Best Casinos Not On GamstopOnline Casino Zonder CruksNon Gamstop CasinosCasino En Ligne Retrait ImmédiatBest Non Gamstop Casinos

Similar interests

(800) 350-9497
August 4, 2020
RBC Life Sciences Reports 16% Second Quarter Sales Growth

PRNewswire
IRVING, Texas
(NASDAQ-OTCBB:RBCL)

 

Irving, Texas (RBC Life Sciences: OTCBB: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.8 million for the second quarter ended June 30, 2020, compared to net sales of $6.8 million for the same period during 2009, an increase of 16%. Net sales for the six months ended June 30, 2020 also increased 16% to $14.8 million compared to net sales of $12.8 million during the same period in 2009.

 

 

For the second quarter of 2010, the Company reported net earnings of $172,000, or $0.01 per share, compared to net earnings of $277,000, or $0.01 per share, during the same quarter in 2009. Net earnings for the six months ended June 30, 2020 were $383,000, or $0.02 per share, compared to $106,000, or $0.00 per share, during the same period in 2009.

 

 

"We are pleased to report year over year sales growth in both of our industry segments as well as significant improvement in earnings during the first six months of 2010," said RBC Life Sciences President and CEO, Clinton H. Howard. "We are particularly pleased with continued recovery of our international licensee business after the challenges we faced in that market last year."

Net sales to licensees, which represent 59% of consolidated net sales, increased 28% during the first six months of 2010 over the comparable period in 2009.

About RBC Life Sciences Through wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

 

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

 

 

Contacts:

Steve Brown

972-893-4000

 

[email protected]


 

RBC Life Sciences - Second Quarter 2010

Page 2

 

RBC Life Sciences, Inc.

Summary Results of Operations

(in thousands, except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

Quarters Ended June 30,

 

 

 

2010

 

 

2009

 

 

 

 

 

 

 

Net sales

$

7,838

 

$

6,759

Gross profit

 

4,182

 

 

3,521

Operating profit

 

357

 

 

508

Earnings before income taxes

 

318

 

 

466

Provision for income taxes

 

146

 

 

189

Net earnings

 

172

 

277

 

 

 

 

 

 

 

Earnings per share - basic and diluted

$

0.01

 

$

0.01

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

21,922

 

 

21,922

Weighted average shares outstanding - diluted

 

22,387

 

 

22,477

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended June 30,

 

 

 

2010

 

 

2009

 

 

 

 

 

 

 

Net sales

$

14,820

 

$

12,775

Gross profit

 

7,045

 

 

6,660

Operating profit

 

757

 

 

347

Earnings before income taxes

 

679

 

 

263

Provision for income taxes

 

296

 

 

157

Net earnings

 

383

 

106

 

 

 

 

 

 

 

Earnings per share - basic and diluted

$

0.02

 

$

0.00

 

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

21,922

 

 

21,920

Weighted average shares outstanding - diluted

 

22,322

 

 

22,509

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


RBC Life Sciences - Second Quarter 2010
Page 3

 

RBC Life Sciences, Inc.

Condensed Balance Sheets

(in thousands)

(unaudited)

 

 

 

June 30,

 

 

December 31,

 

 

 

2010

 

 

2009

Assets

 

 

 

 

 

Cash and cash equivalents

$

3,697

 

$

3,972

Inventories

 

4,804

 

 

5,344

Other current assets

 

2,002

 

 

1,914

 

Total current assets

 

10,503

 

 

11,230

Other assets

 

7,207

 

 

7,383

 

Total assets

$

17,710

 

$

18,613

 

 

 

 

 

 

 

Liabilities and shareholders' equity

 

 

 

 

 

Accounts payable and accrued liabilities

$

2,444

 

$

2,729

Deferred revenue

 

2,715

 

 

3,669

Other current liabilities

 

163

 

 

156

 

Total current liabilities

 

5,322

 

 

6,554

Other liabilities

 

2,758

 

 

2,840

Shareholders' equity

 

9,630

 

 

9,219

 

Total liabilities and shareholders' equity

$

17,710

 

$

18,613

 
 
© 2010 RBC Life Sciences